Deborah Griffin, Teva Pharmaceutical Industries Limited’s Chief Accounting Officer, will step down from her role as Chief Accounting Officer, effective February 15, 2021, and will remain with the Teva Group until officially retiring at the end of the third quarter of 2021 to ensure an orderly transition. The company announced the appointment of Mr. Andrew Weil as Chief Accounting Officer. Mr. Weil will join Teva on February 15, 2021, as Teva’s Group Chief Accounting Officer. Mr. Weil will be relocating to Israel on July 1, 2021, and will be based out of Teva’s headquarters. Mr. Weil, served for 14 years as Executive Vice President, Chief Financial Officer of GTB (formerly known as Team Detroit). Prior to that, Mr. Weil served in several senior finance related leadership roles at the Ford Motor Company, including as their Americas Audit Director, and also worked as a Senior Associate in Coopers & Lybrand, L.L.P., and as a Senior Accountant at Ernst & Young LLP. Mr. Weil holds an MBA from Columbia Business School and a BS in Business Administration from the State University of New York at Buffalo, and is a Certified Public Accountant and a Certified Internal Auditor.